Reports Q2 revenue $45.3M, consensus $43.24M. “Silk Road is the leading force in stroke prevention for patients with severe carotid artery stenosis, and our second quarter results demonstrate the strong momentum behind TCAR as the gold standard in carotid stenting,” said Erica Rogers, CEO of Silk Road Medical. “Our next generation technology coupled with our expanding field presence further strengthen our category leadership in the treatment of carotid artery disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical Reports Second Quarter 2023 Financial Results
- Is SILK a Buy, Before Earnings?
- Silk Road Medical price target lowered to $13 from $27 at Wolfe Research
- DraftKings upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- Silk Road Medical Tanks after CMS Decision on Stent Coverage Spooks Investors